177 related articles for article (PubMed ID: 31687646)
21. Denosumab for treating aneurysmal bone cysts in children.
Raux S; Bouhamama A; Gaspar N; Brugières L; Entz-Werlé N; Mallet C; Dijoud F; Gouin F; Marec-Bérard P
Orthop Traumatol Surg Res; 2019 Oct; 105(6):1181-1185. PubMed ID: 31358461
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab.
Deodati A; Fintini D; Levtchenko E; Rossi M; Ubertini G; Segers H; Battafarano G; Cappa M; Del Fattore A
J Endocrinol Invest; 2022 Jan; 45(1):159-166. PubMed ID: 34216372
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Toxicity of Calcitonin Treatment in Children with Cherubism: A Single-Center Cohort Study.
Schreuder WH; Meijer EB; Cleven AHG; Edelenbos E; Klop C; Schreurs R; de Jong RT; van Maarle MC; Horsthuis RBG; de Lange J; van den Berg H
J Bone Miner Res; 2023 Dec; 38(12):1822-1833. PubMed ID: 37823782
[TBL] [Abstract][Full Text] [Related]
24. Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases.
Kurucu N; Akyuz C; Ergen FB; Yalcin B; Kosemehmetoglu K; Ayvaz M; Varan A; Aydin B; Kutluk T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286564
[TBL] [Abstract][Full Text] [Related]
25. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
26. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
27. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
Lipplaa A; Dijkstra S; Gelderblom H
Curr Opin Oncol; 2019 Jul; 31(4):329-335. PubMed ID: 30844887
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.
Reid IR; Sharma S; Kalluru R; Eagleton C
Calcif Tissue Int; 2016 Sep; 99(3):322-5. PubMed ID: 27193832
[TBL] [Abstract][Full Text] [Related]
29. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Boyce AM
Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
[TBL] [Abstract][Full Text] [Related]
30. Effect of Denosumab on Femoral Periprosthetic BMD and Early Femoral Stem Subsidence in Postmenopausal Women Undergoing Cementless Total Hip Arthroplasty.
Aro HT; Nazari-Farsani S; Vuopio M; Löyttyniemi E; Mattila K
JBMR Plus; 2019 Oct; 3(10):e10217. PubMed ID: 31687650
[TBL] [Abstract][Full Text] [Related]
31. Can denosumab be a substitute, competitor, or complement to bisphosphonates?
Kim SY; Ok HG; Birkenmaier C; Kim KH
Korean J Pain; 2017 Apr; 30(2):86-92. PubMed ID: 28416991
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
33. Denosumab Treatment for Aggressive Multiple Recurrent Familial Central Giant-cell Granulomas.
Rytkönen E; Ottavainen V; Rytkönen A; Uusitalo S; Lehenkari P; Sándor GK
Ann Maxillofac Surg; 2018; 8(2):265-269. PubMed ID: 30693243
[TBL] [Abstract][Full Text] [Related]
34. Denosumab: a potential treatment option for aneurysmal bone cyst of the atlas.
Patel RS; Dhamne CA; Gopinathan A; Kumar N; Kumar N
Eur Spine J; 2018 Jul; 27(Suppl 3):494-500. PubMed ID: 29470716
[TBL] [Abstract][Full Text] [Related]
35. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
Deveci MA; Paydaş S; Gönlüşen G; Özkan C; Biçer ÖS; Tekin M
Acta Orthop Traumatol Turc; 2017 Jan; 51(1):1-6. PubMed ID: 27784623
[TBL] [Abstract][Full Text] [Related]
36. Man of Steel Syndrome: Silicone and Mineral Oil Injections With Associated Hypercalcemia, Hypophosphatemia, and Proximal Muscle Weakness.
Shirvani A; Palermo NE; Holick MF
JBMR Plus; 2019 Oct; 3(10):e10208. PubMed ID: 31687644
[TBL] [Abstract][Full Text] [Related]
37. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.
Roux S; Massicotte MH; Huot Daneault A; Brazeau-Lamontagne L; Dufresne J
Bone; 2019 Mar; 120():482-486. PubMed ID: 30572144
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient.
Ntalos D; Priemel M; Schlickewei C; Thiesen DM; Rueger JM; Spiro AS
Case Rep Orthop; 2017; 2017():9125493. PubMed ID: 29181213
[TBL] [Abstract][Full Text] [Related]
39. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
40. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.
Boyce RW; Varela A; Chouinard L; Bussiere JL; Chellman GJ; Ominsky MS; Pyrah IT
Bone; 2014 Jul; 64():314-25. PubMed ID: 24727159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
